Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02061761
Title Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

diffuse large B-cell lymphoma

Hodgkin's lymphoma

non-Hodgkin lymphoma

multiple myeloma

chronic lymphocytic leukemia

Therapies

Nivolumab + Relatlimab

Relatlimab

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.